CMBA
ARQT icon

C.M. Bidwell & Associates’s Arcutis Biotherapeutics ARQT Stock Holding History

C.M. Bidwell & Associates’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,026
Closed -$94.9K – 501
2026
Q1 		$94.9K Sell
4,026
-1,309
-25% -$33.4K 0.04% 178
2025
Q4 		$155K Buy
5,335
+65
+1% +$1.66K 0.07% 154
2025
Q3 		$99.3K Sell
5,270
-15
-0.3% -$237 0.05% 179
2025
Q2 		$74.1K Hold
5,285
– – 0.04% 195
2025
Q1 		$82.7K Buy
+5,285
New +$74.5K 0.05% 173

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

C.M. Bidwell & Associates's ARQT Position: Q2 2026 in Review

C.M. Bidwell & Associates sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 4,026 shares — an estimated $94.9K sold.

C.M. Bidwell & Associates first reported a position in ARQT in Q1 2025 and held it in 5 quarters. The position peaked at $155K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • C.M. Bidwell & Associates reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 4,026 Arcutis Biotherapeutics shares in Q2 2026, an estimated $94.9K.
  • C.M. Bidwell & Associates first reported a position in Arcutis Biotherapeutics in Q1 2025 and held it in 5 quarters.
  • C.M. Bidwell & Associates's Arcutis Biotherapeutics position peaked at $155K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.